Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

American BriVision (Holding) Corp

Initiate an ABV-1601 Phase II Part 1 clinical trial

Not delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
7 Jan 2021
Due
31 Mar 2021
Checked
24 Oct 2026
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“In the first quarter of 2021, we will initiate an ABV-1601 Phase II Part 1 clinical trial for the treatment of major depression disorder”

What we found

Evidence strength A What the grades mean

The company did not initiate the ABV-1601 Phase II Part 1 clinical trial by the first quarter of 2021, as subsequent filings indicate the trial was expected to begin in later periods.

  • A
    American BriVision (Holding) Corp 10-Q filed 2021-05-10 Regulatory filing · published 10 May 2021 · retrieved 24 Oct 2026 · kept permanently by the SEC · fingerprint de5cf632c9ce
    “The following trials are expected to begin in the second or third quarter of 2021:” ✓ confirmed on the page
  • A
    American BriVision (Holding) Corp 10-Q filed 2021-08-12 Regulatory filing · published 12 Aug 2021 · retrieved 24 Oct 2026 · kept permanently by the SEC · fingerprint afbbfd7da0b9
    “The following trials are expected to begin in the fourth quarter of 2021 and first quarter of 2022:” ✓ confirmed on the page

Market reaction: the shares moved +17.9% against the S&P 500 over the three sessions around the disclosure (7 May 2021 to 12 May 2021). What this measures

Checked 24 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical milestone
Indicative materiality
Medium rules
Action
Initiate
Deliverable
ABV-1601 Phase II Part 1 clinical trial
Where
Los Angeles, California
Language
Firm (“will”, “on track to”)
In the company’s control
High
Specificity
High
Depends on
Regulatory

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
  4. Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you American BriVision (Holding) Corp? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-ABVC-021296 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.